Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR) from its SEC filings: 2025 revenue $68.6 million (-8% vs the year before), net margin -639%, free cash flow -$396.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $68.6 million |
| Revenue growth | -8% |
| Net income | -$438.0 million |
| Net margin | -638.9% |
| Free cash flow | -$396.6 million |
| Diluted EPS | $-3.16 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +19582% |
| Cash | $278.7 million |
| Share count, 1 year | +22% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.